Inventiva (NASDAQ:IVA) Coverage Initiated at Barclays

Equities researchers at Barclays started coverage on shares of Inventiva (NASDAQ:IVA) in a research note issued on Tuesday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $18.00 price target on the stock. Barclays‘s price target points to a potential upside of 181.47% from the company’s current price.

A number of other equities research analysts also recently weighed in on IVA. Wolfe Research upgraded shares of Inventiva to a “strong-buy” rating in a research note on Thursday, November 6th. UBS Group started coverage on Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price target on the stock. HC Wainwright set a $24.00 price objective on Inventiva and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen raised Inventiva to a “hold” rating in a research report on Saturday, October 18th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price objective on shares of Inventiva in a report on Tuesday, September 30th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $16.22.

Inventiva Price Performance

NASDAQ:IVA traded down $0.44 during mid-day trading on Tuesday, reaching $6.40. 296,088 shares of the company’s stock were exchanged, compared to its average volume of 636,995. Inventiva has a one year low of $2.23 and a one year high of $7.98. The business’s fifty day simple moving average is $4.96 and its two-hundred day simple moving average is $4.77.

Institutional Trading of Inventiva

Hedge funds have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC lifted its position in Inventiva by 54.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after buying an additional 5,843 shares during the last quarter. Creative Planning bought a new stake in shares of Inventiva in the 2nd quarter worth approximately $32,000. NewEdge Advisors LLC purchased a new stake in shares of Inventiva in the 3rd quarter valued at $116,000. Finally, Millennium Management LLC bought a new position in shares of Inventiva during the 3rd quarter valued at $649,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.